【摘要】 目的　评价新一代磺酰脲类药物格列美脲 (商品名亚莫利 ,Amaryl,安万特公司 )治疗2型糖尿病的有效性和安全性。方法　无磺酰脲类药物继发失效的 2型糖尿病患者 10 4例 ,以 2 :1的比例随机分入格列美脲组和格列苯脲组 ,观察时间为 16周 (8周剂量调整期 ,8周维持期 )。结果格列美脲降血糖的有效率为 88.7% ,格列苯脲组为 83.3% ,两组间差异无显著性。格列美脲组在降低空腹血糖、餐后 2小时血糖和HbA1c方面和格列苯脲同样有效。格列美脲对于餐后 2h血清胰岛素和C肽的升高作用低于格列苯脲 ,但空腹胰岛素及C肽水平两组相似。格列美脲组对肝肾功能和血压无不良影响 ,低血糖的发生率低于格列苯脲组 (18.2 %vs 33.3% ,P <0 .0 5 )。结论　格列美脲治疗 2型糖尿病安全有效。更多还原

【Abstract】 Objective To evaluate the efficacy and safety of new antidiabetic agent glimepiride (Amaryl ) in the treatment of type 2 diabetes. Methods One hundred and four type 2 diabetic patients without the secondary failure to sulfonylureas were randomly assigned to glimepiride group or glibenclamide group in ratio 2:1. The whole observation lasted 16 weeks. Results Similar decreases in fasting blood glucose, 2h postprandial blood glucose and HbA 1c were showed in both glimepiride and glibenclamide groups. Glimepiride had less effect on increasing 2h postprandial serum insulin and C peptide level than glibenclamide did. In glibenclamide group after treating 16 weeks, postprandial serum insulin and C peptide were significantly higher than that before the treatment (P<0.05 and P<0.01 respectively). But there was no difference on the fasting serum insulin and C peptide between the two groups. No adverse effect on liver and kidney function, and blood pressure was found. There was a lower incidence of hypoglycemia by glimepiride than by glibenclamide (18.2% vs 33.3%, P<0.05). Conclusion Glimepiride is effective and safe in the treatment of type 2 diabetes.更多还原